Plasma Protein Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The Plasma Protein Therapeutics Market is Segmented by Product (Immunoglobulin, Albumin, Plasma Derived Factor Vlll, and Others), Application (Hemophilia, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiencies, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

Market Snapshot

Plasma Protein Therapeutics Market Overview
Study Period: 2018- 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.3 %
Plasma Protein Therapeutics Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The plasma protein therapeutics market studied has been projected to register a CAGR of nearly 5.3% over the forecast period 2021-2026.

The COVID-19 pandemic is expected to have a significant impact on the global market. In the context of the COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on effective and rapid technologies for the fast diagnosis of COVID-19 and developing vaccines and new therapeutics to overcome the current situation. The COVID-19 is also affecting the global economy by directly affecting production and demand and creating supply chain and market disruption, with financial impact on the firms and financial markets. The current COVID-19 pandemic has also temporarily impacted plasma donation globally, affecting the plasma protein therapeutics market. However, researchers are focusing on plasma-based therapeutics to identify whether these therapies have any promising role in treating the COVID-19 virus. For instance, in April 2020, Kamada Ltd. and Kedrion Biopharma, two biopharmaceutical companies specialized in plasma-derived protein therapeutics, entered a global collaboration for the development, manufacturing, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential treatment for COVID-19 patients.

In April 2020, the Indian Council of Medical Research (ICMR) pursued the participation of researchers for conducting a clinical trial of convalescent plasma therapy to treat critically ill COVID-19 patients and floated a protocol for it. In May 2020, BioAegis Therapeutics started researching its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), believing it as a viable therapeutic option for patients suffering from severe lung injury due to COVID-19.

The major factors that are leading to the growth of the market include the increasing prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders. Along with these factors, the rise in the geriatric population across the globe is a major reason for market growth as elderly people are more prone to neurological disorders.

Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting the market growth. The current happening research and development in the plasma protein segment are anticipated to drive its use through several applications. The increase in the usage of therapeutic protein drugs in the treatment of a wide range of clinical symptoms is projected to generate unique growth opportunities for this market in the coming years.

However, the stringent regulations for the handling of plasma protein products and the lack of proper reimbursement policies are the major drawbacks that are hindering the market growth.

Scope of the Report

As per the scope of the report plasma protein therapy, treats distinct medical conditions, restoring missing or inadequate proteins found in plasma to allow their receivers to lead healthier and more productive lives. The patients that rely upon plasma protein therapies generally require regular infusions for the duration of their lives.

The plasma protein therapeutics market is segmented by product (immunoglobulin, albumin, plasma derived factor VII, and other products), application (hemophilia, idiopathic thrombocytopenic purpura, primary immunodeficiencies, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above-mentioned segments.

By Product
Plasma Derived Factor Viii
Other Products
By Application
Idiopathic Thrombocytopenic Purpura
Primary Immunodeficiencies
Other Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Albumin Segment is Expected to be the Fastest-growing Segment over the Forecast Period

Hemophilia is a unique bleeding disorder of genetic origin that prevents the normal clotting of blood. The major symptom of this disorder is uncontrolled and often causes spontaneous bleeding in different areas of the body. The amount of bleeding depends on the severity of hemophilia. According to the World Federation of Hemophilia report 2019, the number of people identified with Hemophilia increased from 78,629 in 1999 to 210,454 in 2018. Additionally, as per the Global Hemophilia Care 2019 report, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have a severe version of the most undiagnosed disease. Hemophilia A is the most prevalent type of the condition, with an incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide born with this disorder. Hemophilia B occurs in approximately 1 in 20,000 newborn males across the world. The increasing prevalence of hemophilia and the huge patient pool are expected to trigger market growth during the forecast period. Moreover, the increasing R&D research on the development of new therapeutics and product launches are expected to boost the segment growth over the forecast period. For instance, in October 2018, the United States Food and Drug Administration (FDA) approved Roche’s Hemlibra for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, newborns, and the elderly, with hemophilia A without factor VIII inhibitors. The increasing geriatric population is also expected to boost demand for plasma protein therapeutics.

Plasma Protein Therapeutics Market Key Trends

North America Dominates the Market and Similar is Expected Over the Forecast Period

North America is expected to dominate the overall plasma protein therapeutics market throughout the forecast period. The market growth is due to factors like the increasing prevalence and incidence of autoimmune and neurological diseases. The United States is expected to be the largest market in this region.

The well-established healthcare infrastructure-focused market players on R&D for plasma protein therapeutics, coupled with recent product launches and the rising burden of autoimmune disorders, are primary growth factors for the market in the United States. According to the Centers for Disease Control and Prevention (CDC), in 2018, about 70% of people with hemophilia in the United States receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. ​According to the United States Arthritis Foundation, arthritis is the leading cause of disability among adults. By conservative estimates, about 54 million adults were diagnosed with arthritis, and almost 300,000 children are suffering from arthritis or rheumatic condition (as of 2017-2018). According to a study published by Derek Weycker, in October 2019, the annual incidence of immune thrombocytopenia (ITP) in the United States was 6.1 per 100,000 persons, higher among females versus males (6.7 vs. 5.5), and highest among children aged between 0 and 4 years (8.1) and adults aged 65 years and above (13.7). Furthermore, there has been an increased focus on convalescent plasma therapy to treat COVID-19 in the United States. In April 2020, Johns Hopkins got the FDA approval to test blood plasma therapy to treat COVID-19 patients. The United States Food and Drug Administration issued guidance to provide recommendations for investigational convalescent plasma therapy. Thus, the market for plasma protein therapeutics is projected to experience significant growth in the United States.

The increasing geriatric population in this region also increases the patient pool, like the elderly are more prone to neurological diseases. Furthermore, beneficial government initiatives, escalating awareness levels among the blood donors, the existence of advanced protein fractioning procedures, greater per capita income in developed countries, and an increase in the number of research partnerships are some of the drivers expected to increase market growth the region.

Plasma Protein Therapeutics Market Growth Rate

Competitive Landscape

The plasma protein therapeutics market is moderately competitive and consists of several major players. Some companies currently dominating the market are Takeda Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, SA, CSL Behring, Biotest AG, Baxter, China Biologic Products Holdings Inc. al Company Ltd, Octapharma USA Inc., Grifols SA, and CSL Behring.

Recent Developments

  • In February 2021, Biotest became Germany's first plasma protein manufacturer to produce an investigational hyper immunoglobulin preparation against COVID-19.
  • In July 2020, Grifols SA signed an agreement with GC Pharma Group to acquire its Montreal-based plasma fractionation facility and two purification facilities with 11 United States-based plasma collection centers.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Incidence of Autoimmune and Neurological Diseases

      2. 4.2.2 Rise in Research and Development in the Plasma Protein

    3. 4.3 Market Restraints

      1. 4.3.1 Strict Regulations for the Handling of Plasma Protein Products

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 Immunoglobulin

      2. 5.1.2 Albumin

      3. 5.1.3 Plasma Derived Factor Viii

      4. 5.1.4 Other Products

    2. 5.2 By Application

      1. 5.2.1 Hemophilia

      2. 5.2.2 Idiopathic Thrombocytopenic Purpura

      3. 5.2.3 Primary Immunodeficiencies

      4. 5.2.4 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Takeda Pharmaceutical Company Ltd

      2. 6.1.2 Octapharma USA Inc.

      3. 6.1.3 Grifols SA

      4. 6.1.4 CSL Behring

      5. 6.1.5 Biotest AG

      6. 6.1.6 Baxter

      7. 6.1.7 China Biologic Products Holdings Inc.

      8. 6.1.8 Kedrion SpA

      9. 6.1.9 Shire PLC

      10. 6.1.10 Bio Products Laboratory

      11. 6.1.11 ADMA Biologics Inc.

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Plasma Protein Therapeutics Market market is studied from 2018 - 2026.

The Global Plasma Protein Therapeutics Market is growing at a CAGR of 5.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Octapharma USA Inc., Grifols,S.A., BiotestAG, CSL Behring, Takeda Pharmaceutical Company Ltd are the major companies operating in Global Plasma Protein Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!